MADISON, Wis. / Oct 08, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
| Third quarter 2024 webcast & conference call details | |||
Date: | Tuesday, November 5, 2024 | ||
Time: | 5 p.m. ET | ||
Webcast: | The live webcast can be accessed at www.exactsciences.com | ||
Telephone: | Domestic callers, dial 888-330-2384 | ||
| International callers, dial +1 240-789-2701 | ||
| Access code for both domestic and international callers: 4437608 | ||
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
| Last Trade: | US$41.58 |
| Daily Change: | -0.68 -1.61 |
| Daily Volume: | 3,118,185 |
| Market Cap: | US$7.700B |
April 14, 2025 March 31, 2025 February 19, 2025 January 21, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
